Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
| العنوان: | Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR |
|---|---|
| المؤلفون: | Aleksandr Suvorov, Goranova-Marinova, Sanjay K. Aggarwal, Gianluca Gaidano, Douglas E. Joshua, Nehal Mohamed, W. J. Chng, H. Goldschmidt, Meletios A. Dimopoulos, Albert Oriol, Thierry Facon, Heinz Ludwig, Laura Rosiñol, Katja Weisel, Heidi H. Gillenwater, Shibao Feng, Philippe Moreau, Luděk Pour, Roman Hájek, Tomas Pika, Ruben Niesvizky, Antonio Palumbo |
| المصدر: | Leukemia r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Phases of clinical research, Gastroenterology, Dexamethasone, Bortezomib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, Humans, Lenalidomide, Chromosome Aberrations, Salvage Therapy, business.industry, Hazard ratio, Remission Induction, Hematology, Pomalidomide, Prognosis, Carfilzomib, 3. Good health, Surgery, Thalidomide, Survival Rate, Oncology, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Female, Original Article, Neoplasm Grading, Neoplasm Recurrence, Local, business, Multiple Myeloma, Oligopeptides, 030215 immunology, medicine.drug, Follow-Up Studies |
| الوصف: | The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n = 97 (25%); Vd, n = 113 (28%)) and 575 (73%) had standard-risk cytogenetics (Kd, n = 284 (75%); Vd, n = 291 (72%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.45-0.92; P = 0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33-0.58; P < 0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved >= CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk. |
| تدمد: | 1476-5551 0887-6924 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5085835f8dacb4137116949dc42fe6c3Test https://pubmed.ncbi.nlm.nih.gov/28025582Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5085835f8dacb4137116949dc42fe6c3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765551 08876924 |
|---|